- Kuida is the first CBD skincare portfolio of products launched
in Colombia from a federally
approved cannabis company
- Company has fulfilled E.U. cosmetic product regulatory
requirements for seven Kuida® products
- Initial UK import anticipated for Q4 2019
- Company has received a "no objection" letter from TSXV for
distribution of the Kuida products in the UK
- UK skincare market estimated at US$3.8
billion in 2018 (Source: Euromonitor)
TORONTO, Oct. 15, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, announced today it has
completed the EU cosmetic regulatory process for seven Kuida
products, and has received a "no objection" letter from TSXV with
respect to distribution of these products in the UK.
Tejinder Virk, President, Khiron
Europe, commented, "The fulfillment of EU cosmetic regulatory
requirements allows the Company to bring our proven product line
into the sophisticated and growing European skincare market, where
we expect to rapidly build and grow Kuida's market share. We will
initially focus on import and marketing in UK, with our first sales
expected in Q1 2020, before expanding to Spain, Germany and the broader European market,
subject to the specific requirements of individual member states
and TSXV approval."
Kuida®, the first consumer brand of Khiron's wellness business
unit, brings the benefits of cannabidiol (CBD) to a comprehensive
portfolio of skin and body care products for women. Kuida was
launched in Colombia in
October 2018 through retail,
wholesale and online channels and is now available nationwide and
through e-commerce channels. As the Company expands Kuida®
distribution in Europe, the brand
will be a featured exhibitor at Cosmoprof Worldwide Bologna 2020,
which attracted over 265,000 visitors in 2019 and is the largest
such event to learn more about market leading products and to place
orders.
For more information on Kuida® please
visit https://kuidaskincare.com/en/
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is
currently facilitating testing to meet and surpass all license
requirements for commercial cannabis derived products.
With a focused regional strategy and patient oriented approach,
the Company combines global scientific expertise, agricultural
advantages, branded product market entrance experience and
education to drive prescription and brand loyalty to address
priority medical conditions such as chronic pain, epilepsy,
depression and anxiety in the Latin American market of over 620
million people. The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres,
together with an experienced executive team, and a knowledgeable
Board of Directors that includes former President of Mexico, Vicente
Fox.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities in
the United States. The securities
have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "U.S. Securities Act") or
any state securities laws and may not be offered or sold within
the United States or to U.S.
Persons (as such term is defined in Regulation S under the U.S.
Securities Act) unless registered under the U.S. Securities Act and
applicable state securities laws or an exemption from such
registration is available.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found
at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-to-commercialize-kuida-brand-in-uk-300938068.html
SOURCE Khiron Life Sciences Corp.